Teva's Drug IP Deal With Gilead Not Pay To Delay, Jurors Hear
Teva's counsel defended the generic-drug maker Tuesday during opening statements in a California trial over claims it reached an anticompetitive deal with Gilead over two HIV medications, saying it settled a...To view the full article, register now.
Already a subscriber? Click here to view full article